Holte H - Search Results

1

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A; Lymphoma/Leukemia Molecular Profiling Project. Bea S, et al. Among authors: holte h. Blood. 2005 Nov 1;106(9):3183-90. doi: 10.1182/blood-2005-04-1399. Epub 2005 Jul 26. Blood. 2005. PMID: 16046532 Free PMC article.

2

T-cell receptor tau delta +/CD3+4-8-T- cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases.

Alfsen GC, Beiske K, Holte H, Hovig E, Deggerdal A, Sandlie I, Widing E, Slørdahl S, Klepper LK, Sizoo W, et al. Alfsen GC, et al. Among authors: holte h. Blood. 1991 May 1;77(9):2023-30. Blood. 1991. PMID: 1826854 Free article.

3

Cyclic AMP has the ability to influence multiple events during B cell stimulation.

Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB. Holte H, et al. Eur J Immunol. 1988 Sep;18(9):1359-66. doi: 10.1002/eji.1830180909. Eur J Immunol. 1988. PMID: 2458941

4

Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets.

Beiske K, Clark EA, Holte H, Ledbetter JA, Smeland EB, Godal T. Beiske K, et al. Among authors: holte h. Int J Cancer. 1988 Oct 15;42(4):521-8. doi: 10.1002/ijc.2910420409. Int J Cancer. 1988. PMID: 2459071

5

Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma.

Holte H, de Lange Davies C, Beiske K, Stokke T, Marton PF, Smeland EB, Høie J, Kvaløy S. Holte H, et al. Int J Cancer. 1989 Dec 15;44(6):975-80. doi: 10.1002/ijc.2910440605. Int J Cancer. 1989. PMID: 2606582

6

The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas.

Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T. Holte H, et al. Int J Cancer. 1987 May 15;39(5):590-4. doi: 10.1002/ijc.2910390508. Int J Cancer. 1987. PMID: 3106247

7

Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas.

Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB. Erikstein BK, et al. Among authors: holte h. Br J Haematol. 1993 Mar;83(3):392-8. doi: 10.1111/j.1365-2141.1993.tb04662.x. Br J Haematol. 1993. PMID: 8097923

8

Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas.

Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB. Stokke T, et al. Among authors: holte h. Br J Cancer. 1998 Jun;77(11):1832-8. doi: 10.1038/bjc.1998.304. Br J Cancer. 1998. PMID: 9667654 Free PMC article.

9

Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas.

Stokke T, Smeland EB, Kvaløy S, Holte H. Stokke T, et al. Among authors: holte h. Br J Cancer. 1998 Jun;77(11):1839-41. doi: 10.1038/bjc.1998.305. Br J Cancer. 1998. PMID: 9667655 Free PMC article.

10

[Primary non-Hodgkin's lymphoma of the brain].

Galteland E, Sivertsen EA, Lote K, Holte H, Kvaløy S. Galteland E, et al. Among authors: holte h. Tidsskr Nor Laegeforen. 1998 Nov 30;118(29):4524-6. Tidsskr Nor Laegeforen. 1998. PMID: 9889638 Norwegian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

287 results

Search Page